Arrayit (OTCMKTS:ARYC – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Institutional and Insider Ownership
42.7% of Telesis Bio shares are held by institutional investors. 58.0% of Arrayit shares are held by company insiders. Comparatively, 30.2% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Get
Arrayit alerts:
Profitability
This table compares Arrayit and Telesis Bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Arrayit | N/A | N/A | N/A |
| Telesis Bio | -251.04% | -73.65% | -51.19% |
Analyst Ratings
This is a breakdown of current ratings for Arrayit and Telesis Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Arrayit | 0 | 0 | 0 | 0 | N/A |
| Telesis Bio | 0 | 0 | 2 | 0 | 3.00 |
Telesis Bio has a consensus price target of $5.00, suggesting a potential upside of 257.14%.
Valuation & Earnings
This table compares Arrayit and Telesis Bio's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Arrayit | N/A | N/A | N/A | N/A | N/A |
| Telesis Bio | $11.04 million | 3.74 | -$38.96 million | ($1.80) | -0.78 |
Arrayit has higher earnings, but lower revenue than Telesis Bio.
Volatility and Risk
Arrayit has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
About Arrayit
(Get Rating)
Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.
About Telesis Bio
(Get Rating)
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Receive News & Ratings for Arrayit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrayit and related companies with MarketBeat.com's FREE daily email newsletter.
